MimiVax is a privately held, clinical-stage biotechnology company focused on the development and commercialization of immunotherapeutic vaccines and targeted therapies for the treatment of cancer. Our proprietary product portfolio is based on technology licensed from Roswell Park Cancer Institute that targets survivin, a cell-survival protein that is present in most cancers and rarely detectable in normal tissue. Our therapies are designed to stimulate immune responses to control tumor growth and recurrence.
SurVaxM, our lead immunotherapeutic vaccine, demonstrated safety and tolerability in a Phase I study in people with malignant gliomas (brain tumors). SurVaxM is currently being evaluated in a Phase II clinical trial in adults with newly diagnosed glioblastoma, and a Phase I clinical trial in combination with REVLIMID® (lenalidomide) as a maintenance therapy for adults with multiple myeloma (a form of blood cancer).
With a team of experienced scientists and leading clinicians. as well as the support of our clinical trial collaborators, patients and investors, we are committed to pursuing the best path to deliver on the promise of SurVaxM and other products to improve the lives of people with cancer.